Substance abuse and addiction represent profound public health challenges, particularly within Indigenous communities in Canada, where historical trauma, systemic inequities, and cultural disconnection have exacerbated these issues. Traditional medical and therapeutic approaches have often fallen short in addressing the complex needs of these populations, leaving a critical gap in effective treatment options. Recent research into psychedelic therapy, particularly with psilocybin (the active compound in “magic mushrooms”), has shown promising results in addiction recovery and mental health treatment. This article explores the current state of substance abuse among Indigenous peoples in Canada, the limitations of conventional treatments, emerging evidence on psilocybin-assisted therapy, and the potential to address stigma and integrate culturally sensitive approaches to save lives.

The Serious Issues of Substance Abuse in Indigenous Communities in Canada
Indigenous peoples in Canada, including First Nations, Métis, and Inuit populations, face disproportionately high rates of substance abuse and related harms. According to recent data, substance use disorders are a leading cause of disability and premature death in these communities. Statistics Canada reports that First Nations youth aged 15 to 24 die by suicide approximately six times more often than non-Indigenous youth, with suicide rates among Inuit youth reaching 24 times the national average. This alarming trend is often linked to co-occurring substance use disorders, with at least 20% of individuals with mental illness also experiencing a substance use disorder, a rate that can rise to 50% among those with schizophrenia.
The opioid crisis has further intensified the situation, with opioid-related deaths continuing to rise due to the contamination of the illicit drug supply with fentanyl and its analogs. Indigenous communities, particularly in rural and northern regions, are disproportionately affected by this epidemic, compounded by socio-structural factors such as stigma, housing instability, and limited access to health services. The Canadian Alcohol and Drugs Survey (CADS) from 2019 indicates that while overall illegal drug use remains low among Canadians (2% reporting hallucinogen use), the prevalence of substance use disorders among Indigenous populations is significantly higher, reflecting deeper systemic issues.
Historical trauma, stemming from colonization, residential schools, and the loss of cultural practices, plays a central role in these statistics. The inter-generational transmission of trauma has led to increased vulnerability to addiction, with many Indigenous individuals turning to substances as a coping mechanism for unresolved pain. Despite these challenges, access to culturally appropriate treatment remains limited, and mainstream interventions often fail to address the spiritual and communal dimensions of healing that are integral to Indigenous worldviews.

Failures of Traditional Medication and Therapy
Traditional medical and therapeutic approaches, including pharmacotherapies and psychosocial interventions, have proven inadequate for many Indigenous individuals struggling with addiction. The effectiveness of treatments for alcohol addiction, for instance, is among the lowest of all mental health disorders, with only 3 licensed pharmacotherapies available and just 9% of affected individuals receiving treatment. For other substances like opioids and methamphetamine, the situation is even bleaker, with few clinically efficacious medications available. This gap is particularly pronounced in Indigenous communities, where mainstream therapies often lack cultural relevance and fail to incorporate traditional healing practices.
Counseling and group therapy, while valuable, frequently face long wait times—averaging 67 days for counseling and 92 days for intensive treatment in Ontario—leaving many without timely support. Moreover, the stigma surrounding mental illness and substance use within and outside Indigenous communities discourages help-seeking behavior, with 75% of Canadians reluctant to disclose a mental health condition to an employer or coworker. For Indigenous peoples, this stigma is compounded by historical mistrust of Western medical systems, rooted in past abuses and the marginalization of traditional knowledge.
Indigenous-led research has highlighted the need for culturally sensitive interventions. Projects like those supported by the Native Women’s Association of Canada emphasize the importance of understanding traditional knowledge and natural laws around substances like cannabis, yet similar efforts for psychedelics remain underdeveloped. The failure of conventional approaches to reduce relapse rates and address root causes such as trauma and social disconnection underscores the urgent need for innovative solutions like psilocybin-assisted therapy.

Emerging Evidence on Psilocybin and Psychedelic Therapy for Addiction
Psilocybin, a naturally occurring psychedelic compound found in certain mushrooms, has garnered significant attention for its therapeutic potential in treating addiction and mental health disorders. Recent studies suggest that psilocybin, when combined with psychotherapy, can produce rapid and lasting reductions in addictive behaviors by promoting neuroplasticity—the growth of new nerve connections—and altering patterns of thought and emotion.
Clinical trials conducted globally, including in Canada, have demonstrated promising outcomes. A longitudinal survey of Canadians receiving compassionate access to psilocybin-assisted psychotherapy under Section 56 exemptions since 2020 found significant alleviation of anxiodepressive symptoms in patients with life-threatening illnesses, with potential applications for addiction. The Government of Canada’s investment of nearly $3 million in 2023 to fund clinical trials exploring psilocybin-assisted psychotherapy for alcohol use disorder, treatment-resistant depression, and end-of-life distress further validates this approach. Preliminary evidence from these trials suggests that psilocybin can break addictive cycles, with participants reporting reduced cravings and improved well-being.
Naturalistic studies provide additional support. Research among a rural Indigenous community in Canada found sustained reductions in problematic use of cocaine, alcohol, and tobacco following an ayahuasca-based intervention (which contains dimethyltryptamine, a related psychedelic compound), with participants describing complete cessation and enhanced quality of life. A study in a Canadian setting also associated psychedelic use with reduced daily opioid use among people who use illicit drugs, aligning with global findings that link psilocybin use to lower rates of opioid, alcohol, and stimulant use disorders.
The mechanism behind these effects may involve psilocybin’s action as a serotonin 2A receptor agonist, which can restore molecular dysfunction in addiction and enhance emotional processing. A small study of 15 heavy smokers receiving three doses of psilocybin during a 15-week cessation program reported an 80% abstinence rate at six-month follow-up, far exceeding the effectiveness of traditional nicotine replacement therapies. These findings, while requiring further validation through randomized controlled trials (RCTs), suggest that psilocybin could offer a transformative tool for addiction recovery.

Cultural Relevance and Potential for Indigenous Communities
The use of psychedelics, including psilocybin, has deep historical roots in Indigenous cultures worldwide, where they have been employed for spiritual healing and communal rituals for millennia. In Canada, Indigenous researchers at Vancouver Island University’s Naut’sa mawt Centre for Psychedelic Research are exploring how psilocybin and other psychedelics can address intergenerational trauma, end-of-life distress, and conditions like PTSD and fibromyalgia. This work emphasizes the integration of Indigenous knowledge, guided by Elders, to develop culturally meaningful treatments.
For instance, Georgina Martin, co-lead of the centre, advocates for psychedelic-assisted therapy that respects traditional medicines and ensures mutual benefit with Indigenous communities, such as the Snuneymuxw First Nation. Similarly, Monnica Williams is investigating ketamine-assisted therapy and potential collaborations with Indigenous organizations like Dilico Anishinabek Family Care, aiming to create culturally useful interventions. These efforts challenge the Western biomedical model’s focus on individual pathology, instead prioritizing reconnection to self, community, and spiritual practices—key elements of Indigenous healing.

Addressing Stigma and Saving Lives
Despite the potential, psychedelics face significant stigma, particularly within Indigenous communities where historical exploitation and cultural appropriation have fostered skepticism. The rapid commercialization of psychedelic therapies risks misappropriating traditional knowledge, as noted in discussions by the Canadian Public Health Association, which calls for a balanced approach that respects Indigenous rights under the United Nations Declaration on the Rights of Indigenous Peoples. This stigma is reinforced by decades of prohibition, initiated in 1970 when the U.S. classified psychedelics as Schedule I substances, a policy that spread internationally and halted research for over 50 years.
Breaking this stigma requires Indigenous-led initiatives, open dialogues on intellectual property, and benefit-sharing, as suggested by researchers like Nicole Redvers of the Deninu K’ue First Nation. Establishing formal surveillance programs alongside compassionate access, as proposed in recent studies, could build trust and demonstrate safety. The success of psilocybin trials in controlled settings, with less than 0.1% reporting adverse effects, challenges the narrative of psychedelics as inherently dangerous, offering a foundation to shift public perception.
The life-saving potential of psilocybin-assisted therapy is clear. With Indigenous youth suicide rates soaring and opioid overdoses claiming lives daily, innovative treatments could prevent thousands of deaths annually. Alberta’s regulatory guidelines and Quebec’s public funding of psilocybin therapy signal a growing acceptance that, if extended to Indigenous communities with cultural sensitivity, could transform outcomes. Advocacy for policy reform, training Indigenous healers, and integrating psychedelics into holistic care models are critical steps to save lives and honor Indigenous sovereignty over their healing practices.

Conclusion
The crisis of substance abuse in Indigenous communities in Canada demands urgent action beyond the limitations of traditional medication and therapy. Emerging evidence on psilocybin-assisted therapy offers a beacon of hope, with studies indicating its efficacy in breaking addictive cycles and addressing trauma. By integrating Indigenous knowledge and addressing stigma, this approach could provide a culturally resonant solution to save lives and foster resilience. As research progresses, collaborative efforts between Indigenous leaders, researchers, and policymakers will be essential to ensure that psilocybin therapy becomes a safe, effective, and respected tool for addiction recovery in Canada’s First Nations and Indigenous communities.

Please contact us or reach out to drphillocybin@gmail.com for more information and resources around the subject of addiction recovery and options for Psychedelic therapy in Canada.